Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Société FrançAise de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4533-4540

  Damaj, Gandhi ^a   Duhamel, Alain ^b   Robin, Marie ^d   Beguin, Yves ^z   Michallet, Mauricette ^g   Mohty, Mohamad ^h   Vigouroux, Stephane ⁱ   Bories, Pierre ^j   Garnier, Alice ^e   El Cheikh, Jean ^k   Bulabois, Claude Eric ^l   Huynh, Anne ^m   Bay, Jacques Olivier ⁿ   Legrand, Faeyzeh ^o   Deconinck, Eric ^p   Fegueux, Nathalie ^q   Clement, Laurence ^r   Dauriac, Charles ^s   Maillard, Natacha ^t   Cornillon, Jér̂ome ^u   Ades, Lionel ^v   Guillerm, Gaelle ^w   Schmidt Tanguy, Aline ^x   Marjanovic, Zora ^f   Park, Sophie ^f   Rubio, Marie Thér̀ese ^f   Marolleau, Jean Pierre ^a   Garnier, Federico ^y   Fenaux, Pierre ^v   Yakoub Agha, Ibrahim ^c   more..

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Régional Universitaire CHRU   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k INSTITUT PAOLI CALMETTES   (France)

^l GRENOBLE UNIVERSITY HOSPITAL   (France)

^m CHU PURPAN   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o UNIVERSITY HOSPITAL OF NICE   (France)

^p UNIVERSITY HOSPITAL OF BESANÇON   (France)

^q MONTPELLIER UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY HOSPITAL OF NANCY   (France)

^s RENNES UNIVERSITY HOSPITAL   (France)

^t POITIERS UNIVERSITY HOSPITAL   (France)

^u Institut de Cancerologie de la Loire   (France)

^v UNIVERSITÉ PARIS 13   (France)

^w BREST UNIVERSITY HOSPITAL   (France)

^x ANGERS UNIVERSITY HOSPITAL   (France)

^y Service de Biostatistique Direction Prélèvement Greffe Organes Tissus   (France)

^z UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; WHOLE BODY RADIATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84871752557     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.3499     Document Type: Article

References (20)

1. Yakoub-Agha I, de La Salmoniè re P, Ribaud P, et al: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: A long-term study of 70 patients - Report of the French Society of Bone Marrow Transplantation. J Clin Oncol 18:963-971, 2000
2. de Witte T, Hagemeijer A, Suciu S, et al: Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: Final results of a prospective randomized European Intergroup Trial. Haematologica 95:1754-1761, 2001
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232, 2009
4. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569, 2010
5. Yakoub-Agha I, Mesnil F, Kuentz M, et al: Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24:5695-5702, 2006
6. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 33:451-458, 1976
7. Swerdlow S, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France, International Agency for Research on Cancer, 2008
8. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
9. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006
10. Kalbfleisch JD, Prentiss R: The Statistical Analysis of Failure Time Data (ed 2). Hoboken, NJ, John Wiley & Sons, 2002
11. Boehm A, Walcherberger B, Sperr WR, et al: Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: A single-center experience. Biol Blood Marrow Transplant 17:133-140, 2011
12. Remberger M, Ackefors M, Berglund S, et al: Improved survival after allogeneic hematopoietic stem cell transplantation in recent years: A single-center study. Biol Blood Marrow Transplant 17:1688-1697, 2011
13. Vicente D, Lamparelli T, Gualandi F, et al: Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant 40:349-354, 2007
14. Lübbert M, Bertz H, Rüter B, et al: Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 44:585-588, 2009
15. Kantarjian HM, O'Brien S, Huang X, et al: Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: Comparison with historical experience. Cancer 109:1133-1137, 2007
16. Cogle CR, Imanirad I, Wiggins LE, et al: Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. Clin Adv Hematol Oncol 8:40-46, 2010
17. Field T, Perkins J, Huang Y, et al: 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45:255-260, 2010
18. Kim DY, Lee JH, Park YH, et al: Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 47:374-379, 2011
19. Horwitz ME: Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 23:197-202, 2011
20. Buchholz S, Dammann E, Stadler M, et al: Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 88:52-60, 2012